New Delhi:
Investment under the Production-Linked Incentive (PLI) scheme for bulk drugs has crossed ₹5,210 crore as of June 2026, with 39 projects for manufacturing 28 active pharmaceutical ingredients and key starting materials commissioned, according to the Union government.
The Department of Pharmaceuticals said the scheme was aimed at strengthening domestic manufacturing of critical pharmaceutical ingredients, reducing import dependence and encouraging technology adoption.
The bulk drugs PLI scheme was approved in 2020 with a financial outlay of ₹6,940 crore. Beneficiary companies had recorded sales of ₹3,792.49 crore, including exports worth ₹560.16 crore, while generating 5,127 jobs as of June.
Several major manufacturing projects have also been commissioned under the scheme, including a Penicillin G facility at Kakinada in Andhra Pradesh with an investment of ₹2,270 crore. The government said the initiative was helping expand domestic pharmaceutical manufacturing capacity.